NYSE:CNMD - CONMED Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $104.60
  • Forecasted Upside: -13.13 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$120.41
▲ +1.96 (1.65%)
1 month | 3 months | 12 months
Get New CONMED Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CNMD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CNMD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$104.60
▼ -13.13% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for CONMED in the last 3 months. The average price target is $104.60, with a high forecast of $145.00 and a low forecast of $76.00. The average price target represents a -13.13% upside from the last price of $120.41.
Buy
The current consensus among 6 contributing investment analysts is to buy stock in CONMED. This rating has held steady since April 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/28/2021Piper SandlerBoost Price TargetOverweight$95.00 ➝ $145.00Low
i
7/30/2020Stifel NicolausBoost Price TargetBuy$82.00 ➝ $100.00High
i
7/30/2020SVB LeerinkBoost Price TargetMarket Perform$82.00 ➝ $92.00High
i
Rating by R. Newitter at SVB Leerink LLC
7/29/2020Piper SandlerBoost Price TargetOverweight$90.00 ➝ $95.00Medium
i
4/30/2020SVB LeerinkReiterated RatingMarket PerformLow
i
Rating by R. Newitter at SVB Leerink LLC
4/30/2020Stifel NicolausBoost Price TargetBuy$65.00 ➝ $82.00Medium
i
4/30/2020Piper SandlerLower Price TargetOverweight$110.00 ➝ $90.00Medium
i
4/30/2020Needham & Company LLCReiterated RatingHoldMedium
i
Rating by Michael Matson at Needham & Company LLC
4/23/2020JPMorgan Chase & Co.Lower Price TargetOverweight$136.00 ➝ $76.00Medium
i
4/14/2020BarclaysReiterated RatingBuy$110.00Medium
i
3/10/2020Piper SandlerLower Price Target$130.00 ➝ $110.00High
i
3/10/2020Needham & Company LLCReiterated RatingHoldHigh
i
Rating by Michael Matson at Needham & Company LLC
11/26/2019Needham & Company LLCDowngradeBuy ➝ HoldHigh
i
11/12/2019JPMorgan Chase & Co.Initiated CoverageOverweight$136.00Medium
i
10/31/2019Needham & Company LLCBoost Price TargetBuy$111.00 ➝ $115.00High
i
10/4/2019Needham & Company LLCBoost Price TargetBuy$101.00 ➝ $111.00Medium
i
8/22/2019Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$88.00 ➝ $110.00High
i
8/1/2019Stifel NicolausBoost Price TargetBuy$97.00 ➝ $99.00High
i
8/1/2019BarclaysBoost Price TargetOverweight$96.00 ➝ $105.00High
i
4/17/2019Stifel NicolausInitiated CoverageBuy ➝ Buy$95.00Medium
i
4/16/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$87.00 ➝ $94.00High
i
4/15/2019BarclaysBoost Price TargetOverweight ➝ Overweight$85.00 ➝ $92.00Low
i
2/27/2019Needham & Company LLCBoost Price TargetBuy$87.00Low
i
2/19/2019BarclaysInitiated CoverageEqual Weight ➝ Overweight$85.00High
i
Rating by Kristen Stewart at Barclays PLC
1/23/2019Needham & Company LLCReiterated RatingBuy ➝ Buy$86.00 ➝ $79.00High
i
10/16/2018BarclaysSet Price TargetEqual Weight ➝ Equal Weight$78.00High
i
8/30/2018SVB LeerinkBoost Price TargetMarket Perform$76.00 ➝ $81.00Low
i
8/2/2018Needham & Company LLCBoost Price TargetBuy$73.00 ➝ $83.00High
i
4/26/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$71.00 ➝ $73.00High
i
2/1/2018Needham & Company LLCBoost Price TargetBuy ➝ Buy$58.00 ➝ $71.00High
i
11/17/2017Needham & Company LLCReiterated RatingBuy$58.00N/A
i
11/3/2017KeyCorpReiterated RatingHoldN/A
i
11/3/2017Piper Jaffray CompaniesReiterated RatingHold$46.00N/A
i
9/1/2017Needham & Company LLCReiterated RatingBuy$57.00Low
i
8/25/2017KeyCorpReiterated RatingHoldLow
i
7/27/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$54.00 ➝ $57.00Low
i
4/27/2017LADENBURG THALM/SH SHDowngradeBuy ➝ Neutral$50.00 ➝ $48.00High
i
4/27/2017Needham & Company LLCBoost Price TargetBuy ➝ Buy$48.00 ➝ $54.00High
i
2/2/2017Needham & Company LLCReiterated RatingBuy$48.00N/A
i
11/23/2016SVB LeerinkReiterated RatingHold ➝ NeutralN/A
i
11/18/2016Needham & Company LLCBoost Price TargetBuy$49.00 ➝ $53.00N/A
i
10/28/2016SVB LeerinkReiterated RatingMarket Perform$47.00 ➝ $43.00N/A
i
7/28/2016SVB LeerinkDowngradeOutperform ➝ Market Perform$56.00 ➝ $47.00N/A
i
Rating by Richard Newitter at SVB Leerink LLC
4/28/2016SVB LeerinkReiterated RatingBuyN/A
i
Rating by Richard Newitter at SVB Leerink LLC
4/28/2016Needham & Company LLCBoost Price TargetBuy$48.00 ➝ $49.00N/A
i
Rating by Michael Matson at Needham & Company LLC
3/7/2016Needham & Company LLCReiterated RatingBuyN/A
i
Rating by Michael Matson at Needham & Company LLC
(Data available from 3/5/2016 forward)
CONMED logo
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures worldwide. It offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including diagnostic and therapeutic products for use in gastroenterology procedures, and products for the treatment of diseases of the biliary structures, as well as cardiac monitoring products comprising ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
Read More

Today's Range

Now: $120.41
$117.86
$120.61

50 Day Range

MA: $118.71
$111.90
$126.38

52 Week Range

Now: $120.41
$37.66
$129.18

Volume

6,447 shs

Average Volume

284,067 shs

Market Capitalization

$3.49 billion

P/E Ratio

N/A

Dividend Yield

0.65%

Beta

1.55

Frequently Asked Questions

What sell-side analysts currently cover shares of CONMED?

The following Wall Street sell-side analysts have issued research reports on CONMED in the last twelve months: Barclays PLC, JPMorgan Chase & Co., Needham & Company LLC, Piper Sandler, Stifel Nicolaus, SVB Leerink LLC, TheStreet, and Zacks Investment Research.
View the latest analyst ratings for CNMD.

What is the current price target for CONMED?

5 Wall Street analysts have set twelve-month price targets for CONMED in the last year. Their average twelve-month price target is $104.60, suggesting a possible downside of 13.1%. Piper Sandler has the highest price target set, predicting CNMD will reach $145.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $76.00 for CONMED in the next year.
View the latest price targets for CNMD.

What is the current consensus analyst rating for CONMED?

CONMED currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CNMD will outperform the market and that investors should add to their positions of CONMED.
View the latest ratings for CNMD.

What other companies compete with CONMED?

How do I contact CONMED's investor relations team?

CONMED's physical mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The company's listed phone number is 315 797 8375. The official website for CONMED is www.conmed.com.